中国肿瘤外科杂志2026，Vol.18Issue(2)：186-191,6.DOI:10.3969/j.issn.1674-4136.2026.02.013
2025版EAU肌层浸润性和转移性膀胱癌指南更新解读
Interpretation of the updates to the 2025 EAU Guidelines on muscle-invasive and metastatic bladder cancer
摘要
Abstract
The 2025 European Association of Urology(EAU)guidelines on muscle-invasive and metastatic bladder cancer(MIBC)have systematically optimized the diagnostic and therapeutic flows for MIBC.In terms of molecular biomarkers,the guidelines have introduced a new recommendation for the use of fibroblast growth factor receptor 3(FGFR3)alterations to select patients with unresectable or metastatic urothelial carcinoma for treatment with erdafitinib.Significant modifications have been made to the recommendations regarding perioperative radiotherapy.For patients with pathological T3b to T4 diseases,lymph node positivity,or positive surgical margin after radical cystectomy,a weak recommendation for adjuvant radiotherapy has been proposed.In female patients,the guidelines have a higher recommendation level for the implementation of sexual-preserving techniques in eligible cases.The guidelines emphasize the strong correlation between the surgical volume of radical cystectomy in hospitals and patient outcomes,recommending that centers performing radical cystectomy should conduct more than 20 cases annually.Additionally,the guidelines have provided comprehensive updates on adjuvant therapy,treatment of metastatic disease,and follow-up strategies.These updates offer more practical guidance for clinical decision-making and provide substantial support for improving patient outcomes.关键词
肌层浸润性膀胱癌/转移性膀胱癌/欧洲泌尿外科学会/指南更新/精准治疗Key words
Muscle-invasive bladder cancer/Metastatic bladder cancer/European Association of Urology/Guidelines update/Precise diagnosis引用本文复制引用
牛嘉晖,邱雪峰,郭宏骞..2025版EAU肌层浸润性和转移性膀胱癌指南更新解读[J].中国肿瘤外科杂志,2026,18(2):186-191,6.基金项目
中德科学基金研究交流中心中德合作交流项目(M-0670) （M-0670）
江苏省医学重点学科/实验室建设单位(JSDW202221) （JSDW202221）
